At a glance
ClinicalIndex Comparison Record- ✓Histologic or cytologic proof of adenocarcinoma of stomach or gastroesophageal junction
- ✓Peritoneal disease: either positive peritoneal cytology or carcinomatosis on laparoscopy/laparotomy
- ✓Completion of preoperative systemic chemotherapy and preoperative laparoscopic HIPEC
- ✓ECOG performance status 0-2
- ✕Non-peritoneal distant metastases (liver, CNS, lung)
- ✕Active infections (e.g., pneumonia or wound infection) that would preclude protocol therapy
- ✕Unstable angina or NYHA grade II or greater congestive heart failure
- ✕Known life-threatening or severe hypersensitivity to protocol systemic chemotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
In Brief
A Phase 2 clinical trial evaluating Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, and 1 other intervention for Gastric Adenocarcinoma and 2 related conditions. Completed, enrolled 24 participants across 1 site.
Detailed Summary
This phase II trial studies how well heated mitomycin and cisplatin during surgery work in treating patients with stomach or gastroesophageal cancer. Drugs used in chemotherapy, such as mitomycin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more tumor cells.
Study Details
Timeline
Interventions
Given intraperitoneally
Undergo HIPEC
Given intraperitoneally